Drug intelligence / Profile preview

recombinant human interleukin-10

Development stage: Phase 2
Lead developer: Merck
Modality: Cytokines & Interferons → Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

Recombinant human interleukin-10 is an anti-inflammatory, immunomodulatory cytokine that regulates mucosal inflammation. It is a 161 amino acid protein that inhibits the production of pro-inflammatory cytokines such as interferon gamma, tumor necrosis factor alpha, and interleukin 2. It also suppresses delayed type hypersensitivity responses and stimulates Th2 cell responses. In clinical trials, it has been studied for treating inflammatory bowel disease, particularly Crohn's disease, and more recently as an immunotherapy for cancer.

Brand names: Tenovil
Other names: IL-10IL10IL 10rhIL-10rhIL10rhIL 10pegylated IL-10AM0010AM-0010AM 0010

Targets

IL10RA (Interleukin-10 Receptor)

Beyond the preview

Go deeper on recombinant human interleukin-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant human interleukin-10.

Explore the full profile